307 - A Prospective Randomized Trial Comparing Conditioning with Either BEAM or High-Dose Melphalan Prior to Autologous Transplantation for Patients with Multiple Myeloma: An Evaluation of Interim Safety in Early Recovery Phase

Publication Title

Transplantation and Cellular Therapy

Authors

Megumi Bailey, Swedish Medical Center, Seattle, Washington, United States.Follow
Tenzin Tsomo, 1Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WAFollow
Neil Bailey, Swedish Cancer Center, Seattle, WAFollow
Tori Braun, Swedish Cancer Center, Seattle, WA
Chiachun Lu, Swedish Cancer Center, Seattle, WA
Carol Dean, Swedish Cancer Center, Seattle, WA
Shannon Williams, Swedish Cancer Center, Seattle, WA
Gayle Funk, Swedish Cancer Center, Seattle, WA
Joanna Fesler, Swedish Cancer Center, Seattle, WA
Sonia Glennie, Swedish Cancer Center, Seattle, WA
Judson Hall, Swedish Cancer Center, Seattle, WA
Vanessa Dunleavy, Swedish Cancer Center, Seattle, WA
Daniel N Egan, Department of Medicine, Swedish Medical Center, Seattle, WA, United States.Follow
Raya Mawad, Department of Medical Oncology, Swedish Cancer Institute, Seattle, WA, USAFollow
Livia Hegerova, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, Washington.Follow
Krish Patel, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USAFollow
John M PagelFollow
William Bensinger, Myeloma and Transplant Program, Swedish Cancer Institute, Seattle, WA, United StatesFollow

Document Type

Abstract

Publication Date

3-18-2022

Keywords

washington; swedish; swedish cancer

Clinical Institute

Cancer

Specialty/Research Institute

Hematology

Specialty/Research Institute

Oncology